Production (Stage)
Structure Therapeutics Inc.
GPCR
$24.55
-$0.10-0.41%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 18.60% | 23.94% | 53.40% | 71.32% | 74.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 75.89% | 51.84% | 75.31% | 28.20% | 62.93% |
| Operating Income | -75.89% | -51.84% | -75.31% | -28.20% | -62.93% |
| Income Before Tax | -79.70% | -46.46% | -44.46% | -12.17% | -44.89% |
| Income Tax Expenses | 237.93% | 143.59% | -77.28% | -55.08% | 16.00% |
| Earnings from Continuing Operations | -79.88% | -48.88% | -42.39% | -11.83% | -44.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -79.88% | -48.88% | -42.39% | -11.83% | -44.85% |
| EBIT | -75.89% | -51.84% | -75.31% | -28.20% | -62.93% |
| EBITDA | -76.26% | -51.42% | -74.81% | -27.67% | -62.38% |
| EPS Basic | -46.06% | -20.34% | 4.64% | 13.42% | 25.71% |
| Normalized Basic EPS | -45.93% | 8.72% | 3.24% | 13.16% | 25.70% |
| EPS Diluted | -46.06% | -20.34% | 4.64% | 13.42% | 25.71% |
| Normalized Diluted EPS | -45.93% | 8.72% | 3.24% | 13.16% | 25.70% |
| Average Basic Shares Outstanding | 23.15% | 23.72% | 49.31% | 29.17% | 94.98% |
| Average Diluted Shares Outstanding | 23.15% | 23.72% | 49.31% | 29.17% | 94.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |